{"id":780651,"date":"2023-08-29T09:24:35","date_gmt":"2023-08-29T13:24:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\/"},"modified":"2023-08-29T09:24:35","modified_gmt":"2023-08-29T13:24:35","slug":"prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\/","title":{"rendered":"Prelude Therapeutics to Participate in Three Healthcare Investor\u00a0Conferences in September"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WILMINGTON, Del., Aug.  29, 2023  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0yVFkiVP-PS8_7wcTuWIgzLKx4dQSOpZ6sJ-blAU8BdNzriH8Ujmu6Hl_mtCR2fq7wN9jSGVwEp2cOXXtZOou1jc_20klx96ddjDF8SoHXs=\" rel=\"nofollow noopener\" target=\"_blank\">Prelude Therapeutics Incorporated<\/a> (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences. Details are as follows:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"2\">\n            <strong>Wells Fargo 18<\/strong><br \/>\n            <sup><br \/>\n              <strong>th<\/strong><br \/>\n            <\/sup><br \/>\n            <strong> Annual Healthcare Conference Boston<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:3%;width:3%;min-width:3%\">\u00a0<\/td>\n<td style=\"max-width:97%;width:97%;min-width:97%\">\n            <strong>Kris Vaddi, Ph.D.,<\/strong> Chief Executive Officer will participate in a Fireside chat on <strong>Wednesday, September 6, at 4:30 p.m. ET.<\/strong> The live webcast is available <a href=\"https:\/\/event.webcasts.com\/starthere.jsp?ei=1631364&amp;tp_key=e935c18469&amp;tp_special=8\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>. Dr. Vaddi and <strong>Laurent Chardonnet, Chief Financial Officer of Prelude<\/strong>, will host one-on-one meetings at the conference.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\">\n            <strong>H. C. Wainwright 25<\/strong><br \/>\n            <sup><br \/>\n              <strong>th<\/strong><br \/>\n            <\/sup><br \/>\n            <strong> Annual Healthcare Investment Conference<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\n            <strong>Dr. Vaddi<\/strong> and <strong>Jane Huang, MD, President and Chief Medical Officer<\/strong> will participate in a Fireside chat on <strong>Monday, September 11, at 1:30 p.m. ET. <\/strong>The live webcast is available <a href=\"https:\/\/journey.ct.events\/view\/7e03e9e0-edc0-4f10-a981-82774961a991\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>. Dr. Vaddi, along with Dr. Huang and Mr. Chardonnet will host one-on-one investor meetings at the conference.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\">\n            <strong>Morgan Stanley 21<\/strong><br \/>\n            <sup><br \/>\n              <strong>st<\/strong><br \/>\n            <\/sup><br \/>\n            <strong> Annual Global Healthcare Conference<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>On <strong>Tuesday, September 12, at 4:55 p.m. ET,<\/strong><strong>Dr. Vaddi and Dr. Huang<\/strong> will participate in a Fireside chat. The live webcast is available <a href=\"https:\/\/cc.webcasts.com\/morg007\/091123a_js\/?entity=70_6NMRE1I\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>. Dr. Vaddi, Dr. Huang and Mr. Chardonnet will conduct one-on-one investor meetings at the conference.<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"left\">\n        <strong>About Prelude Therapeutics<br \/><\/strong>Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company\u2019s diverse pipeline is comprised of highly differentiated, potentially best\/first-in-class proprietary small molecule compounds aimed at addressing specific pathways for\u00a0cancers with selectable underserved patients. Prelude\u2019s pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1, PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645 a next generation CDK4\/6 inhibitor<strong>, <\/strong>PRT3789 an IV administered, potent and highly selective SMARCA2 degrader, and a preclinical oral candidate targeting SMARCA2.<\/p>\n<p align=\"left\">For more information, visit our <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2eQG0igotjGWxzVG7rvHC0xSHcvHYnoWajHGqWuerKTZui-ixOk5YR8Ih15bAbMD0NxS1BxMJ0vT9VHh_e0zYQ==\" rel=\"nofollow noopener\" target=\"_blank\">website<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UZrzQPhrYb9F84Vj-9gmnPxKw6rolQco4pG-DavJdCtnaGGXM0mRLB7C-cYl4KiJheiFPH77nPLpfPsBjfX_L9H4b3EvapKI4TUoN9-tuSWow6eb1S-DaWyYbmUzz7PUv21ZFqIFDWO98FKC8Yuc4Q==\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BzHUctQ7cJNA2c9rEm9QoNt9NaD614NEXFgpeaEG08E3SoTpUMBYucIXApJTokd6gXbmFGm4UA2umutbOUtejA==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>.<\/p>\n<p align=\"left\">\n        <strong>Investor Contact:<\/strong>\u00a0<br \/>Lindsey Trickett\u00a0<br \/>Vice President, Investor Relations\u00a0<br \/>240.543.7970\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nadvVpO1KFvXpXxMrAFouzH8fQBlZIX5TnDW02e6OYDo8c2kIkRPY8tPk-zF1tptjG3hS0ScjfeuxTNX0zzmS-L-xflPqrcg7z7-pE0T4Zc=\" rel=\"nofollow noopener\" target=\"_blank\">ltrickett@preludetx.com<\/a><\/p>\n<p align=\"left\">\n        <strong>Media Contact:<\/strong>\u00a0<br \/>Helen Shik<br \/>Shik Communications<br \/>617.510.4373<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=snC3O1U1PwStnOLAJyz-cyJc8PJzD6V2XMGmSYNBbvXoBu5y9CEZdTxys42d2Ri8T-W0i5tP0f_f8y39ErQQPRek61THMRoi3JGlQaVGXXOYIc8r44S-Ve6qB54cHhwa\" rel=\"nofollow noopener\" target=\"_blank\">helen@shikcommunications.com<\/a><\/p>\n<p align=\"left\">\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMjMzMiM1Nzg3MDUwIzIyMDIzMjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NzM2YWVhMmEtZmM5ZC00YzJmLWFhYmQtYmI3NGEwMTQ1ZjI0LTEyMTM4NzY=\/tiny\/Prelude-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WILMINGTON, Del., Aug. 29, 2023 (GLOBE NEWSWIRE) &#8212; Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences. Details are as follows: Wells Fargo 18 th Annual Healthcare Conference Boston \u00a0 Kris Vaddi, Ph.D., Chief Executive Officer will participate in a Fireside chat on Wednesday, September 6, at 4:30 p.m. ET. The live webcast is available here. Dr. Vaddi and Laurent Chardonnet, Chief Financial Officer of Prelude, will host one-on-one meetings at the conference. H. C. Wainwright 25 th Annual Healthcare Investment Conference \u00a0 Dr. Vaddi and Jane Huang, MD, President and Chief Medical Officer will participate in a Fireside chat on Monday, September 11, at 1:30 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Prelude Therapeutics to Participate in Three Healthcare Investor\u00a0Conferences in September&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-780651","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prelude Therapeutics to Participate in Three Healthcare Investor\u00a0Conferences in September - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prelude Therapeutics to Participate in Three Healthcare Investor\u00a0Conferences in September - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WILMINGTON, Del., Aug. 29, 2023 (GLOBE NEWSWIRE) &#8212; Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences. Details are as follows: Wells Fargo 18 th Annual Healthcare Conference Boston \u00a0 Kris Vaddi, Ph.D., Chief Executive Officer will participate in a Fireside chat on Wednesday, September 6, at 4:30 p.m. ET. The live webcast is available here. Dr. Vaddi and Laurent Chardonnet, Chief Financial Officer of Prelude, will host one-on-one meetings at the conference. H. C. Wainwright 25 th Annual Healthcare Investment Conference \u00a0 Dr. Vaddi and Jane Huang, MD, President and Chief Medical Officer will participate in a Fireside chat on Monday, September 11, at 1:30 &hellip; Continue reading &quot;Prelude Therapeutics to Participate in Three Healthcare Investor\u00a0Conferences in September&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-29T13:24:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMjMzMiM1Nzg3MDUwIzIyMDIzMjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Prelude Therapeutics to Participate in Three Healthcare Investor\u00a0Conferences in September\",\"datePublished\":\"2023-08-29T13:24:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\\\/\"},\"wordCount\":323,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMjMzMiM1Nzg3MDUwIzIyMDIzMjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\\\/\",\"name\":\"Prelude Therapeutics to Participate in Three Healthcare Investor\u00a0Conferences in September - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMjMzMiM1Nzg3MDUwIzIyMDIzMjM=\",\"datePublished\":\"2023-08-29T13:24:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMjMzMiM1Nzg3MDUwIzIyMDIzMjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMjMzMiM1Nzg3MDUwIzIyMDIzMjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prelude Therapeutics to Participate in Three Healthcare Investor\u00a0Conferences in September\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prelude Therapeutics to Participate in Three Healthcare Investor\u00a0Conferences in September - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\/","og_locale":"en_US","og_type":"article","og_title":"Prelude Therapeutics to Participate in Three Healthcare Investor\u00a0Conferences in September - Market Newsdesk","og_description":"WILMINGTON, Del., Aug. 29, 2023 (GLOBE NEWSWIRE) &#8212; Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences. Details are as follows: Wells Fargo 18 th Annual Healthcare Conference Boston \u00a0 Kris Vaddi, Ph.D., Chief Executive Officer will participate in a Fireside chat on Wednesday, September 6, at 4:30 p.m. ET. The live webcast is available here. Dr. Vaddi and Laurent Chardonnet, Chief Financial Officer of Prelude, will host one-on-one meetings at the conference. H. C. Wainwright 25 th Annual Healthcare Investment Conference \u00a0 Dr. Vaddi and Jane Huang, MD, President and Chief Medical Officer will participate in a Fireside chat on Monday, September 11, at 1:30 &hellip; Continue reading \"Prelude Therapeutics to Participate in Three Healthcare Investor\u00a0Conferences in September\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-29T13:24:35+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMjMzMiM1Nzg3MDUwIzIyMDIzMjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Prelude Therapeutics to Participate in Three Healthcare Investor\u00a0Conferences in September","datePublished":"2023-08-29T13:24:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\/"},"wordCount":323,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMjMzMiM1Nzg3MDUwIzIyMDIzMjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\/","name":"Prelude Therapeutics to Participate in Three Healthcare Investor\u00a0Conferences in September - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMjMzMiM1Nzg3MDUwIzIyMDIzMjM=","datePublished":"2023-08-29T13:24:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMjMzMiM1Nzg3MDUwIzIyMDIzMjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMjMzMiM1Nzg3MDUwIzIyMDIzMjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Prelude Therapeutics to Participate in Three Healthcare Investor\u00a0Conferences in September"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/780651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=780651"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/780651\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=780651"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=780651"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=780651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}